FRI0508 Experience with Interleukin-1 Inhibitor Canakinumab in Auto-Inflammatory Diseases and Systemic Juvenile Idiopathic Arthritis in Clinical Practice

S.O. Salugina; M. Kaleda; E. Fedorov; I. Nikishina

doi:10.1136/annrheumdis-2016-eular.3889

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Poster Presentations

Other orphan diseases

FRI0508 Experience with Interleukin-1 Inhibitor Canakinumab in Auto-Inflammatory Diseases and Systemic Juvenile Idiopathic Arthritis in Clinical Practice

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Salugina S, Kaleda M, Fedorov E, et al

FRI0508 Experience with Interleukin-1 Inhibitor Canakinumab in Auto-Inflammatory Diseases and Systemic Juvenile Idiopathic Arthritis in Clinical Practice

Annals of the Rheumatic Diseases 2016;75:622.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password